Getinge AB stock (SE0000202624): CEO share purchase draws focus to valuation after US patent setback

Getinge AB shares were in focus on Nasdaq Stockholm on 05/29/2026 after CEO Mattias Perjos acquired 25,000 company shares at a price of SEK 187.70 each, a transaction worth SEK 4,692,500 according to Sweden's Finansinspektionen and market data reported by MarketScreener.MarketScreener as of 05/29/2026

The trade was executed on Nasdaq Stockholm, underlining the Swedish home-market listing and signaling management confidence in the medical-technology group shortly after a legal setback in the United States involving its Maquet cardiovascular subsidiary.MarketScreener as of 05/29/2026

The stock traded around SEK 187.70 on 05/29/2026 on Nasdaq Stockholm, according to the disclosed insider transaction data and contemporaneous price quotes.MarketScreener as of 05/29/2026

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Getinge AB: core business model

Getinge AB focuses on advanced medical-technology systems and services for hospitals and life science customers, earning most of its revenue from equipment and related solutions that support intensive care, surgery, and infection control across global healthcare markets.

Recent corporate actions

Alongside the insider dealing disclosure for 05/29/2026, investors have been weighing the impact of a recent US court decision in which Maquet Cardiovascular, a Getinge subsidiary, lost a patent infringement case tied to heart pump technology against Abiomed, with a federal jury finding that Abiomed did not infringe the asserted patent and also deeming the patent invalid according to Reuters coverage dated 05/23/2026.Reuters as of 05/23/2026

The case centered on Maquet's claims around heart pump devices used in high-risk cardiac procedures, and the adverse verdict in the United States underscores ongoing legal and competitive pressures in the cardiovascular devices segment where US-based Abiomed, now part of Johnson & Johnson, is a key rival.MarketScreener as of 05/24/2026

Valuation metrics and multiples for Getinge AB

With Getinge AB trading at around SEK 187.70 on 05/29/2026 on Nasdaq Stockholm, investors are watching how the combination of insider buying and legal developments feeds into the valuation multiples for the Swedish medtech group.MarketScreener as of 05/29/2026

Aggregator data for the same date indicate standard valuation ratios such as price-to-earnings and enterprise-value-to-EBITDA in line with broader European medical-technology peers, providing context for the CEO's SEK 4.7 million share purchase following the US patent verdict.MarketScreener as of 05/29/2026

Conclusion

The disclosure that CEO Mattias Perjos bought 25,000 Getinge AB shares at SEK 187.70 each on 05/29/2026 highlights insider confidence in the Swedish medtech group in the wake of an unfavorable US patent outcome for its Maquet unit.

Against that backdrop, investors are reassessing the company's valuation metrics on Nasdaq Stockholm, balancing litigation risk in the cardiovascular segment with the long-term demand profile for Getinge's critical-care and surgical solutions.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.